About Intigus Pharmaceutical
Intigus Pharmaceutical is a Healthcare company. It operates as a pharmaceutical solutions for neurological, psychiatric, and pain management in India. Its Indian entity Intigus Pharmaceutical Private Limited reported revenue of ₹7.60 Cr. Intigus Pharmaceutical offers products and services including CNS Medicines and Pain Management Drugs. Its focus areas include Pharmaceuticals, CNS Pharmaceuticals, Neurological Treatments and Psychiatric Drugs.
Company details
Intigus Pharmaceutical is identified as a leader in the CNS segment across India, where high-quality and affordable medicines for neurological and psychiatric conditions have been provided for over five years. Specialized divisions such as Mindax and Brainax are utilized to target disorders like epilepsy, depression, and Parkinsons disease. Expansion into regions like Uttar Pradesh is pursued to enhance accessibility, while a focus on innovation, quality, and ethical practices is maintained to improve patient outcomes and societal impact.
- SectorsHealthcare
- Phone•••• ••••
- Legal Name Intigus Pharmaceutical Private Limited
- Date of Incorporation 15 Feb, 2019
- Jurisdiction Noida, Uttar Pradesh, India
- Annual Revenue₹7.60 Cr
FY 2025 · +81% YoY
- Net Profit₹41 Lakh
FY 2025 · 5% margin
- EBITDA₹62.7 Lakh
FY 2025 · 8% margin
Associated legal entities of Intigus Pharmaceutical
Intigus Pharmaceutical operates through Intigus Pharmaceutical Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Intigus Pharmaceutical Private Limited CIN U51909UP2019PTC113743 | Active | 15 Feb 2019 | Noida, Uttar Pradesh | ₹7.6 Cr | 23 | 3 | View details |
Products & Services of Intigus Pharmaceutical
Intigus Pharmaceutical offers a comprehensive portfolio of products and services, including CNS Medicines and Pain Management Drugs.
Medicines for neurological and psychiatric conditions are developed and supplied to address various disorders.
Treatments for pain conditions are offered as part of the product range.
Board of directors of Intigus Pharmaceutical Private Limited (Intigus Pharmaceutical)
Intigus Pharmaceutical Private Limited is the primary company behind Intigus Pharmaceutical. The board of Intigus Pharmaceutical Private Limited currently have 3 directors; the longest-serving is Vishnu Kumar Singh, appointed in 2019. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vishnu Kumar Singh DIN 08364486 | Director | 15 Feb 2019 | 7 yrs 8 mo | Intigus Pharmaceutical Private Limited |
| Sandeep Tiwari DIN 10381058 | Director | 03 Nov 2023 | 2 yrs 11 mo | Intigus Pharmaceutical Private Limited |
| Arti Singh DIN 10685738 | Director | 27 Jun 2024 | 2 yrs 3 mo | Intigus Pharmaceutical Private Limited |
Financials of Intigus Pharmaceutical
Figures of Intigus Pharmaceutical Private Limited, the primary company behind Intigus Pharmaceutical, for FY 2025. Revenue was ₹7.60 Cr (+81% year on year). Net profit was ₹41 Lakh (5% margin). EBITDA was ₹62.7 Lakh (8% margin). Revenue has grown at a compounded annual rate of +60% over three years and +68% over five years.
- ₹7.60 CrRevenue · FY 2025 · +81% YoY
- ₹41 LakhNet profit · 5% margin
- ₹62.7 LakhEBITDA · 8% margin
- ₹25 LakhPaid-up capital
- 23Employees (provident fund records)
- +60%Revenue CAGR, 3 years
- +68%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Intigus Pharmaceutical Private Limited are on its company page.
Detailed financial statements for Intigus Pharmaceutical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Top companies in Neurology
10 companies that operate in the same segment as Intigus Pharmaceutical (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Intigus Pharmaceutical
The primary company behind Intigus Pharmaceutical, Intigus Pharmaceutical Private Limited, reported revenue of ₹7.60 Cr for FY 2025, up 81% year on year.
Intigus Pharmaceutical is identified as a leader in the CNS segment across India, where high-quality and affordable medicines for neurological and psychiatric conditions have been provided for over five years. Specialized divisions such as Mindax and Brainax are utilized to target disorders like epilepsy, depression, and Parkinsons disease. Expansion into regions like Uttar Pradesh is pursued to enhance accessibility, while a focus on innovation, quality, and ethical practices is maintained to improve patient outcomes and societal impact.
Intigus Pharmaceutical offers CNS Medicines and Pain Management Drugs.
Intigus Pharmaceutical operates through Intigus Pharmaceutical Private Limited.
The legal entities of Intigus Pharmaceutical currently have 3 directors, including Vishnu Kumar Singh, Sandeep Tiwari, Arti Singh.